IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy

Less Invasive Phenotype Found in Isocitrate Dehydrogenase–mutated Glioblastomas than in Isocitrate Dehydrogenase Wild-Type Glioblastomas: A Diffusion-Tensor Imaging Study

(2017) Stephen J. Price et al.   RADIOLOGY

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion

(2016) Tomohiro Kawaguchi et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

(2016) Brigitta G Baumert et al.   LANCET ONCOLOGY

Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection

(2016) Jeffrey S. Wefel et al.   NEURO-ONCOLOGY

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma

(2016) Jan C. Buckner et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO

(2015) David E. Reuss et al.   ACTA NEUROPATHOLOGICA

MR Imaging–Based Analysis of Glioblastoma Multiforme: Estimation ofIDH1Mutation Status

(2015) K. Yamashita et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations

(2015) U. E. Emir et al.   CANCER RESEARCH

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate

(2015) O. C. Andronesi et al.   CLINICAL CANCER RESEARCH

Mutational landscape and clonal architecture in grade II and III gliomas

(2015) Hiromichi Suzuki et al.   NATURE GENETICS

Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma

(2015) Macarena I. de la Fuente et al.   NEURO-ONCOLOGY

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH1R132H mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status

(2015) Jacqueline Kessler et al.   RADIOTHERAPY AND ONCOLOGY

IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma

(2015) Philipp Kickingereder et al.   Scientific Reports

Rapid Intraoperative Molecular Characterization of Glioma

(2015) Ganesh M. Shankar et al.   JAMA Oncology

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

(2015) Yuchen Jiao et al.   Oncotarget

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

(2015) Kasthuri Kannan et al.   Oncotarget

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

(2015) Patrick J. Killela et al.   Oncotarget

Can Diffusion Tensor Imaging Noninvasively Detect IDH1 Gene Mutations in Astrogliomas? A Retrospective Study of 112 Cases

(2014) W. L. Tan et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Extent of Resection of Glioblastoma Revisited: Personalized Survival Modeling Facilitates More Accurate Survival Prediction and Supports a Maximum-Safe-Resection Approach to Surgery

(2014) Nicholas F. Marko et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy

(2014) Giuseppe Minniti et al.   JOURNAL OF NEURO-ONCOLOGY

Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing

(2014) Betty Y. S. Kim et al.   JOURNAL OF NEURO-ONCOLOGY

Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma

(2014) Masayuki Kanamori et al.   JOURNAL OF NEUROSURGERY

Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery

(2014) S. Santagata et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma

(2014) Stefan Pusch et al.   Acta Neuropathologica Communications

TERT promoter mutations in primary and secondary glioblastomas

(2013) Naosuke Nonoguchi et al.   ACTA NEUROPATHOLOGICA

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss

(2013) Hideyuki Arita et al.   ACTA NEUROPATHOLOGICA

Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate

(2013) Ovidiu C. Andronesi et al.   JOURNAL OF CLINICAL INVESTIGATION

Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis

(2013) Hairui Sun et al.   JOURNAL OF NEURO-ONCOLOGY

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

(2013) Jason Beiko et al.   NEURO-ONCOLOGY

From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma

(2013) Gavin P. Dunn et al.   Neurosurgical Focus

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

(2012) Xiao-Yang Liu et al.   ACTA NEUROPATHOLOGICA

Probabilistic Radiographic Atlas of Glioblastoma Phenotypes

(2012) B.M. Ellingson et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

The Definition of Primary and Secondary Glioblastoma

(2012) H. Ohgaki et al.   CLINICAL CANCER RESEARCH

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas

(2012) T. A. Juratli et al.   JOURNAL OF NEURO-ONCOLOGY

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

(2012) Changho Choi et al.   NATURE MEDICINE

Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation

(2012) J. Lazovic et al.   NEURO-ONCOLOGY

Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation

(2012) Sichen Li et al.   NEURO-ONCOLOGY

Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China

(2012) Wei Yan et al.   PLoS One

Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin

(2011) Albert Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

(2011) Whitney B. Pope et al.   JOURNAL OF NEURO-ONCOLOGY

An extent of resection threshold for newly diagnosed glioblastomas

(2011) Nader Sanai et al.   JOURNAL OF NEUROSURGERY

The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

(2010) Fonnet E. Bleeker et al.   ACTA NEUROPATHOLOGICA

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

(2009) Koichi Ichimura et al.   NEURO-ONCOLOGY

EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME

(2009) et al.   NEUROSURGERY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of the IDH1 codon 132 mutation in brain tumors

(2008) Jörg Balss et al.   ACTA NEUROPATHOLOGICA

Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas

(2008) Justin S. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE